Overview
This study will compare the efficacy of telemedicine-delivered cognitive behavioral therapy for insomnia tailored for people using cannabis for sleep (CBTi-CB-TM) to telemedicine-delivered sleep hygiene education (SHE-TM) on sleep, cannabis use, and daytime functioning. We will also evaluate the effects of CBTi-CB-TM on fundamental sleep regulatory system - homeostatic sleep drive - and its association with clinical outcomes.
Eligibility
Inclusion Criteria:
- Self-reported chronic insomnia
- Insomnia Severity Index (ISI) score indicative of at least mild insomnia
- Cannabis Use Disorder Identification Test-Revised (CUDIT-R) indicative of at least problematic cannabis use
- A positive urine drug screen (UDS) for cannabis
- Self-reported use of cannabis to manage insomnia at least three times weekly for the past month
- Stable residence (e.g., stable sleep arrangements), consistent access to Wi-Fi, and ability to travel to Ann Arbor for sleep laboratory assessments
Exclusion Criteria:
- Individuals who do not understand English
- Individuals judged unable to provide informed consent (e.g., intoxication, mental incompetence)
- Diagnosis or high suspicion of a sleep disorder other than insomnia
- Diagnosis of psychotic disorder, bipolar disorder, or post-traumatic stress disorder
- Terminal or progressive physical illness (e.g., cancer) or neurological degenerative disease (e.g., dementia)
- Use of medications known to have initiated their insomnia (e.g., steroids)
- Previous receipt of CBTi
- Self-reported pregnancy
- Self-reported regular work schedule of rotating or night (3rd) shift work.